KLIFO A/S Revenue and Competitors
Estimated Revenue & Valuation
- KLIFO A/S's estimated annual revenue is currently $40.4M per year.
- KLIFO A/S's estimated revenue per employee is $201,000
Employee Data
- KLIFO A/S has 201 Employees.
- KLIFO A/S grew their employee count by -6% last year.
KLIFO A/S's People
Name | Title | Email/Phone |
---|---|---|
1 | Data Manager | Reveal Email/Phone |
2 | Warehouse Coordinator | Reveal Email/Phone |
KLIFO A/S Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $123.6M | 615 | 4% | N/A | N/A |
#2 | $96.9M | 482 | 18% | N/A | N/A |
#3 | $44.8M | 223 | 9% | N/A | N/A |
#4 | $5.6M | 28 | 4% | N/A | N/A |
#5 | $40.4M | 201 | -6% | N/A | N/A |
#6 | $3.4M | 17 | -69% | N/A | N/A |
#7 | $9.2M | 46 | 10% | N/A | N/A |
#8 | $26.5M | 132 | 61% | N/A | N/A |
#9 | $6.8M | 34 | 36% | N/A | N/A |
What Is KLIFO A/S?
KLIFO is a leading drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance drug development projects. At KLIFO, we offer cross-functional consulting and operational solutions spanning all areas of clinical research, clinical trial supply, CMC development, regulatory affairs, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices.
keywords:N/AN/A
Total Funding
201
Number of Employees
$40.4M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
KLIFO A/S News
... Corporation (US), Sharp Packaging Services (US), Biocair (UK), O&M Movianto (US), KLIFO A/S (Denmark), Thermo Fisher Scientific.
Patheon Inc. Sharp Packaging Services; Biocair; Movianto; Klifo A/S. Segmentation. This study includes all forms of segmentation from the region...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $77M | 212 | 0% | N/A |
#2 | $158.4M | 384 | 25% | N/A |
#3 | N/A | 417 | 34% | N/A |
#4 | $320.3M | 789 | 2% | N/A |
#5 | $232.2M | 925 | 8% | N/A |